CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p–XIAP axis

Shang, Jin; Chen, Weimin; Wang, Zhihong; Wei, Tiannan; Chen, Zhizhong; Wu, Wenbing

doi:10.1016/j.exphem.2018.10.011

Cited by 120 publications

(100 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Circ-PAN3 is a newly identi ed circRNA, which is located on 13q12.2 [17]. In recent years, several studies have investigated the role of circ-PAN3 in various diseases [12,13].…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies reported that cyclin D1 could be positively regulated by X-linked inhibitor of apoptosis protein (XIAP) through E3 ligase-mediated phosphorylation [16]. Interestingly, circ-PAN3 could regulate positively XIAP to induce chemo-resistance in acute myeloid leukemia [17]. Although both circ-PAN3 and cyclin D1 are upregulated in several malignancies, the possible role of circ-PAN3 in the regulation of cyclin D1 remains largely unknow.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circular RNA circ-PAN3 (hsa_circ_0100181) Promotes Hepatocellular Carcinoma Growth Through Sponging miR-153 to Elevate Cyclin D1 Expression

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Circular RNAs (circRNAs) are engaged in hepatocellular carcinoma (HCC) progression, but the mechanisms remain to be elucidated. This study aimed to unveil the expression pattern and potential biological mechanisms of a newly indentified circRNA, circ-PAN3, in HCC. Methods: Cell Counting Kit-8 (CCK‐8) assay and colony formation assay were used to assess cell proliferation. Transcription-quantitative PCR (RT-qPCR) analysis and western blot analysis were used to determine the relative expression level of mRNA and protein, respectively. Cell apoptosis assay was used to evaluate the apoptosis rate of transfected cells. CircInteractome and Targetscan were utilized to predict the possible targets of circRNAs and miRNAs, respectively. Luciferase reporter assay and RNA pull-down assay were used to assess the direct interaction of RNAs. HCC cancer xenograft model was used to evaluate the biological process of circ-PAN3 in vivo. Student’s t test, χ2 test or one-way ANOVA was adopted appropriately.Results: Circ-PAN3 was elevated in HCC tissues, and patients with high Circ-PAN3 expression had a poor survival outcome. Knockdown of circ-PAN3 expression suppressed cell viability, colony formation and cell proliferation in vitro and in vivo. Circ-PAN3 elevates cyclin D1 expression to promote HCC progression. Subsequently, using CircInteractome, miR-153 were confirmed to interact with circ-PAN3 and was downregulated by circ-PAN3. Further, using Targetscan, cyclin D1 was validated to interact with miR-153 and was downregulated by miR-153. Addition of miR-153 expression with corresponsive mimics significantly reduced the expression of cyclin D1. Notably, the inhibition of cell viability, colony formation and proliferation induced by knockdown of circ-PAN3 were recovered following the combination with miR-153 inhibitor, cyclin D1, respectively. Conclusion: Together, this study demonstrated that a novel circ-PAN3/miR-153/cyclin D1 axis regulatory axis that promoted HCC progression.

show abstract

“…Circ-PAN3 is a newly identi ed circRNA, which is located on 13q12.2 [17]. In recent years, several studies have investigated the role of circ-PAN3 in various diseases [12,13].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Circular RNA circ-PAN3 (hsa_circ_0100181) Promotes Hepatocellular Carcinoma Growth Through Sponging miR-153 to Elevate Cyclin D1 Expression

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…All these elucidate the potential of circRNAs as markers for diagnosis and therapy of cancers [193][194][195]. It has been found that circRNAs not only contribute to development and metastasis of malignances, but also are involved in chemoresistance [196][197][198][199]. Several oncogenic circRNAs have been found to participate in drug resistance of gastric cancer (Table 12).…”

Section: Circrnas and Chemoresistance In Gastric Cancermentioning

confidence: 94%

Noncoding RNAs in gastric cancer: implications for drug resistance

et al. 2020

View full text Add to dashboard Cite

Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Advanced gastric cancer patients can notably benefit from chemotherapy including adriamycin, platinum drugs, 5-fluorouracil, vincristine, and paclitaxel as well as targeted therapy drugs. Nevertheless, primary drug resistance or acquisition drug resistance eventually lead to treatment failure and poor outcomes of the gastric cancer patients. The detailed mechanisms involved in gastric cancer drug resistance have been revealed. Interestingly, different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are critically involved in gastric cancer development. Multiple lines of evidences demonstrated that ncRNAs play a vital role in gastric cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically summarized the emerging role and detailed molecular mechanisms of ncRNAs impact drug resistance of gastric cancer. Additionally, we propose the potential clinical implications of ncRNAs as novel therapeutic targets and prognostic biomarkers for gastric cancer.

show abstract

“…The establishment of this database may be useful to discover effective targets to overcome drug resistance of CRC cells [158]. Recently, Shang et al found a detailed circPAN3/miR-153-5p/ miR-183-5p/X-linked inhibitor of apoptosis protein (XIAP) interaction in AML, which can be used as a novel target for reversing ADM resistance in AML patients [159]. However, extensive studies are urgently needed to further the understanding of circRNAsassociated drug resistance in various cancers.…”

Section: Circrnas As Novel Targets Reversing Drug Resistance For Cancmentioning

confidence: 99%

Circular RNAs in the tumour microenvironment

Shuai

Gao

et al. 2020

Mol Cancer

View full text Add to dashboard Cite

Background: Circular RNAs (circRNAs) are a new class of endogenous non-coding RNAs (ncRNAs) widely expressed in eukaryotic cells. Mounting evidence has highlighted circRNAs as critical regulators of various tumours. More importantly, circRNAs have been revealed to recruit and reprogram key components involved in the tumour microenvironment (TME), and mediate various signaling pathways, thus affecting tumourigenesis, angiogenesis, immune response, and metastatic progression.Main body of the abstract: In this review, we briefly introduce the biogenesis, characteristics and classification of circRNAs, and describe various mechanistic models of circRNAs. Further, we provide the first systematic overview of the interplay between circRNAs and cellular/non-cellular counterparts of the TME and highlight the potential of circRNAs as prospective biomarkers or targets in cancer clinics. Finally, we discuss the biological mechanisms through which the circRNAs drive development of resistance, revealing the mystery of circRNAs in drug resistance of tumours. Short conclusion:Deep understanding the emerging role of circRNAs and their involvements in the TME may provide potential biomarkers and therapeutic targets for cancer patients. The combined targeting of circRNAs and co-activated components in the TME may achieve higher therapeutic efficiency and become a new mode of tumour therapy in the future.

show abstract

CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p–XIAP axis

Cited by 120 publications

References 44 publications

Circular RNA circ-PAN3 (hsa_circ_0100181) Promotes Hepatocellular Carcinoma Growth Through Sponging miR-153 to Elevate Cyclin D1 Expression

Circular RNA circ-PAN3 (hsa_circ_0100181) Promotes Hepatocellular Carcinoma Growth Through Sponging miR-153 to Elevate Cyclin D1 Expression

Noncoding RNAs in gastric cancer: implications for drug resistance

Circular RNAs in the tumour microenvironment

Contact Info

Product

Resources

About